Last reviewed · How we verify
High-Flow Nasal Oxygen Therapy for Exacerbation of Chronic Pulmonary Obstructive Disease. (OxyCOD)
High-Flow Nasal Oxygen (HFNO) therapy has never been tested against Noninvasive ventilation, the reference standard therapy for acute exacerbation of chronic obstructive pulmonary disease (COPD), in randomized clinical trials. The aim of the present study is to compare the effects of HFNO therapy on arterial blood gas variables over the first 24 hours of therapy, to those of Noninvasive ventilation, in patients experiencing a moderate (i.e. with arterial pH within 7.25-7.35) exacerbation of COPD.
Details
| Lead sponsor | Centre Hospitalier Régional d'Orléans |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 51 |
| Start date | Wed Jun 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Oct 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- Noninvasive ventilation
- High-Flow Nasal Oxygen therapy
Countries
France